アジソン病の世界市場レポート 2025年

アジソン病市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.7％で、32億6,000万米ドルに成長します。予測期間中の成長は、先進治療薬に対する需要の高まり、早期診断への注目の高まり、先天性副腎過形成症例の有病率の増加、遠隔医療サービスの拡大、副腎結核の罹患率の上昇などが要因と考えられます。この時期の主な動向としては、検査手法の発展、ホルモン補充療法の革新、画像技術の改善、長時間作用型注射製剤の開発、診断ツールへの人工知能の統合などが挙げられます。

自己免疫疾患の有病率の上昇は、アジソン病市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が誤って身体の健康な組織を攻撃し、炎症や損傷を引き起こすことで発生します。遺伝的素因、汚染物質や食生活の変化などの環境的影響、ストレスや運動不足などのライフスタイルなどの要因が、自己免疫疾患の発生を増加させています。また、多くの患者が複数の自己免疫疾患を発症するため、これらの疾患の有病率の増加は、アジソン病との併発の可能性を高める。例えば、2024年11月、ドイツを拠点とする団体Versorgungsatlas.deは、2022年に7,324万1,305人の被保険者のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断されたと報告しました。その結果、自己免疫疾患の有病率の増加がアジソン病市場の拡大に拍車をかけています。

アジソン病市場の主要企業は、治療の選択肢を増やし、患者の転帰を改善し、身体本来の副腎機能を刺激することでホルモン補充療法への生涯依存を減らす可能性のある再生療法などの革新的アプローチに注力しています。再生療法は、ヒトの細胞、組織、または臓器を置換または再生し、正常な機能を回復させ、疾患、損傷、変性の場合の治癒を促進することを目的とした医療技術を含みます。例えば、2024年7月、希少疾患の治療を専門とする米国の製薬会社Eton Pharmaceuticals, Inc.は、独自のヒドロコルチゾン内用液ET-400の新薬承認申請（NDA）がFDAに受理されたと発表しました。ET-400は、冷蔵保存を必要とする製剤と比較して、保存・輸送上の利点が改善されています。さらに、錠剤の嚥下が困難な若年患者のニーズを満たすよう液剤の剤形が設計されており、より正確な投与が可能です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界アジソン病 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のアジソン病市場：成長率分析
• 世界のアジソン病市場の実績：規模と成長, 2019-2024
• 世界のアジソン病市場の予測：規模と成長, 2024-2029, 2034F
• 世界アジソン病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のアジソン病市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発性副腎機能不全
• 二次性副腎機能不全
• 三次性副腎機能不全
• 世界のアジソン病市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口コルチコステロイド
• ヒドロコルチゾン
• フルドロコルチゾン
• コルチコステロイド注射
• 世界のアジソン病市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臨床検査
• 画像検査
• 世界のアジソン病市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 診断検査室
• その他のエンドユーザー
• 世界のアジソン病市場、原発性副腎機能不全の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自己免疫アジソン病
• 感染性アジソン病
• 原発性副腎機能不全のその他の原因
• 世界のアジソン病市場二次性副腎機能不全の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 下垂体機能不全
• 視床下部機能障害
• 世界のアジソン病市場、三次性副腎機能不全の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 長期ステロイド使用による視床下部または下垂体の抑制
• 三次性副腎機能不全のその他の原因

第7章 地域別・国別分析

• 世界のアジソン病市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のアジソン病市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• アジソン病市場：競合情勢
• アジソン病市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Sandoz
• Ipsen S.A.
• Neurocrine Biosciences Inc.
• Recipharm AB
• Accord Healthcare
• Eton Pharmaceuticals
• DuoCort Pharma
• Diurnal Group plc
• Roxane Laboratories Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• アジソン病市場2029：新たな機会を提供する国
• アジソン病市場2029：新たな機会を提供するセグメント
• アジソン病市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Addison's disease is a rare condition in which the adrenal glands produce insufficient cortisol and aldosterone due to damage, often caused by an autoimmune response. Symptoms include fatigue, muscle weakness, weight loss, low mood, and skin changes. Lifelong hormone replacement therapy is essential to manage the condition and prevent severe complications such as adrenal crisis.

The primary types of Addison's disease include primary, secondary, and tertiary adrenal insufficiency. Primary adrenal insufficiency occurs when the adrenal glands fail to produce adequate cortisol and, in some cases, aldosterone due to damage or dysfunction. Management involves various drug classes, such as oral corticosteroids, hydrocortisone, fludrocortisone, and corticosteroid injections. Diagnosis typically involves laboratory and imaging tests to assess adrenal gland function. Patient care is facilitated by several end-users, including hospitals, clinics, diagnostic laboratories, and other healthcare providers.

The addison's disease market research report is one of a series of new reports from The Business Research Company that provides addison's disease market statistics, including the addison's disease industry global market size, regional shares, competitors with the addison's disease market share, detailed addison's disease market segments, market trends, and opportunities, and any further data you may need to thrive in the addison's disease industry. This addison's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The addison's disease market size has grown rapidly in recent years. It will grow from $2.05 billion in 2024 to $2.25 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth during the historic period can be attributed to the increasing global incidence of Addison's disease, greater awareness of adrenal insufficiency, rising healthcare expenditure, a higher prevalence of autoimmune diseases, and a growing geriatric population.

The addison's disease market size is expected to see strong growth in the next few years. It will grow to $3.26 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth during the forecast period can be driven by the rising demand for advanced therapeutics, an increased focus on early diagnosis, a growing prevalence of congenital adrenal hyperplasia cases, the expansion of telemedicine services, and a higher incidence of adrenal tuberculosis. Key trends in this period include advancements in laboratory testing methodologies, innovations in hormone replacement therapies, improvements in imaging technologies, the development of long-acting injectable formulations, and the integration of artificial intelligence in diagnostic tools.

The rising prevalence of autoimmune diseases is expected to drive the growth of the Addison's disease market. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy tissues, leading to inflammation and damage. Factors such as genetic predisposition, environmental influences such as pollutants and dietary changes, and lifestyle aspects such as stress and lack of physical activity contribute to the increasing occurrence of autoimmune diseases. The growing prevalence of these conditions also raises the likelihood of co-occurrence with Addison's disease, as many patients develop multiple autoimmune disorders. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%, higher than previous estimates of 3% to 9%. As a result, the increasing prevalence of autoimmune diseases is fueling the expansion of the Addison's disease market.

Leading companies in the Addison's disease market are focusing on innovative approaches such as regenerative therapies to enhance treatment options, improve patient outcomes, and potentially reduce lifelong dependence on hormone replacement therapies by stimulating the body's natural adrenal function. Regenerative therapies involve medical techniques aimed at replacing or regenerating human cells, tissues, or organs to restore normal function and promote healing in cases of disease, injury, or degeneration. For instance, in July 2024, Eton Pharmaceuticals, Inc., a US-based pharmaceutical company specializing in treatments for rare diseases, announced that the FDA had accepted its New Drug Application (NDA) for ET-400, a proprietary hydrocortisone oral solution. ET-400 offers improved storage and transport benefits compared to formulations requiring refrigeration. Additionally, its liquid format is designed to meet the needs of young patients who may struggle with swallowing tablets, allowing for more precise dosing.

In November 2022, Neurocrine Biosciences Inc., a US-based biotech company, acquired Diurnal Group plc for $56.5 million. This acquisition strengthens Neurocrine Biosciences' portfolio in rare endocrine disorders by incorporating Diurnal Group's expertise in adrenal hormone therapies. Diurnal Group plc, a UK-based biotech company, specializes in developing treatments for adrenal insufficiency, including Addison's disease.

Major players in the addison's disease market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz, Ipsen S.A., Neurocrine Biosciences Inc., Recipharm AB, Accord Healthcare, Eton Pharmaceuticals, DuoCort Pharma, Diurnal Group plc, and Roxane Laboratories Inc.

North America was the largest region in the addison's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in addison's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the addison's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The addison's disease market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The addison's disease market also includes sales of adjunct therapies, diagnostic tools, adrenocorticotropic hormone (ACTH) stimulation test kits, blood cortisol, and ACTH testing kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Addison's Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on addison's disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for addison's disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The addison's disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Primary Adrenal Insufficiency; Secondary Adrenal Insufficiency; Tertiary Adrenal Insufficiency
• 2) By Drug Class: Oral Corticosteroid; Hydrocortisone; Fludrocortisone; Corticosteroid Injections
• 3) By Diagnosis: Laboratory Testing; Imaging Testing
• 4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users
• Subsegments:
• 1) By Primary Adrenal Insufficiency: Autoimmune Addison's Disease; Infectious Addison's Disease; Other causes of primary adrenal insufficiency
• 2) By Secondary Adrenal Insufficiency: Pituitary gland dysfunction; Hypothalamic dysfunction
• 3) By Tertiary Adrenal Insufficiency: Hypothalamic or pituitary suppression due to long-term steroid use; Other causes of tertiary adrenal insufficiency
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; Bayer AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Addison's Disease Market Characteristics

3. Addison's Disease Market Trends And Strategies

4. Addison's Disease Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Addison's Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Addison's Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Addison's Disease Market Growth Rate Analysis
• 5.4. Global Addison's Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Addison's Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Addison's Disease Total Addressable Market (TAM)

6. Addison's Disease Market Segmentation

• 6.1. Global Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Adrenal Insufficiency
• Secondary Adrenal Insufficiency
• Tertiary Adrenal Insufficiency
• 6.2. Global Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Corticosteroid
• Hydrocortisone
• Fludrocortisone
• Corticosteroid Injections
• 6.3. Global Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Laboratory Testing
• Imaging Testing
• 6.4. Global Addison's Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic Laboratories
• Other End Users
• 6.5. Global Addison's Disease Market, Sub-Segmentation Of Primary Adrenal Insufficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autoimmune Addison's Disease
• Infectious Addison's Disease
• Other Causes of Primary Adrenal Insufficiency
• 6.6. Global Addison's Disease Market, Sub-Segmentation Of Secondary Adrenal Insufficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pituitary Gland Dysfunction
• Hypothalamic Dysfunction
• 6.7. Global Addison's Disease Market, Sub-Segmentation Of Tertiary Adrenal Insufficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypothalamic or Pituitary Suppression Due to Long-Term Steroid Use
• Other Causes of Tertiary Adrenal Insufficiency

7. Addison's Disease Market Regional And Country Analysis

• 7.1. Global Addison's Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Addison's Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Addison's Disease Market

• 8.1. Asia-Pacific Addison's Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Addison's Disease Market

• 9.1. China Addison's Disease Market Overview
• 9.2. China Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Addison's Disease Market

• 10.1. India Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Addison's Disease Market

• 11.1. Japan Addison's Disease Market Overview
• 11.2. Japan Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Addison's Disease Market

• 12.1. Australia Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Addison's Disease Market

• 13.1. Indonesia Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Addison's Disease Market

• 14.1. South Korea Addison's Disease Market Overview
• 14.2. South Korea Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Addison's Disease Market

• 15.1. Western Europe Addison's Disease Market Overview
• 15.2. Western Europe Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Addison's Disease Market

• 16.1. UK Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Addison's Disease Market

• 17.1. Germany Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Addison's Disease Market

• 18.1. France Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Addison's Disease Market

• 19.1. Italy Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Addison's Disease Market

• 20.1. Spain Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Addison's Disease Market

• 21.1. Eastern Europe Addison's Disease Market Overview
• 21.2. Eastern Europe Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Addison's Disease Market

• 22.1. Russia Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Addison's Disease Market

• 23.1. North America Addison's Disease Market Overview
• 23.2. North America Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Addison's Disease Market

• 24.1. USA Addison's Disease Market Overview
• 24.2. USA Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Addison's Disease Market

• 25.1. Canada Addison's Disease Market Overview
• 25.2. Canada Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Addison's Disease Market

• 26.1. South America Addison's Disease Market Overview
• 26.2. South America Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Addison's Disease Market

• 27.1. Brazil Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Addison's Disease Market

• 28.1. Middle East Addison's Disease Market Overview
• 28.2. Middle East Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Addison's Disease Market

• 29.1. Africa Addison's Disease Market Overview
• 29.2. Africa Addison's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Addison's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Addison's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Addison's Disease Market Competitive Landscape And Company Profiles

• 30.1. Addison's Disease Market Competitive Landscape
• 30.2. Addison's Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Addison's Disease Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. GlaxoSmithKline plc
• 31.4. Amgen Inc.
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Sandoz
• 31.8. Ipsen S.A.
• 31.9. Neurocrine Biosciences Inc.
• 31.10. Recipharm AB
• 31.11. Accord Healthcare
• 31.12. Eton Pharmaceuticals
• 31.13. DuoCort Pharma
• 31.14. Diurnal Group plc
• 31.15. Roxane Laboratories Inc.

32. Global Addison's Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Addison's Disease Market

34. Recent Developments In The Addison's Disease Market

35. Addison's Disease Market High Potential Countries, Segments and Strategies

• 35.1 Addison's Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Addison's Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Addison's Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer